Ulcerative Colitis Clinical Case Review

Sujaata Dwadasi, MD, an IBD Specialist at Carle Foundation Hospital in Illinois, discusses the treatment selected for the case:

“When discussing the therapy for the patient from our case, we want to make sure that we start a biologic therapy, because she does have moderate to severe UC, and per the ACG guidelines, we would want to start a biologic or potentially a small molecule therapy. In addition, there is a high likelihood that she has an IBD arthropathy, as her joint pains really started to worsen the same time as her bowel symptoms were worsening. We discussed starting an anti-TNF therapy, because it would be a monotherapy that would help her luminal disease as well as her joint pains.

[The patient travels] a lot for work, so she would like an injectable option, as she wasn’t sure if she would be able to make every single infusion appointment. So, we discussed the safety and efficacy of adalimumab (Humira, AbbVie).”